Medexus Pharmaceuticals (TSX:MDP) Cyclically Adjusted FCF per Share: C$-0.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
53 GF Score
Price C$5.06
GF Value C$2.06
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Cyclically Adjusted FCF per Share?

Medexus Pharmaceuticals TSX:MDP -1.36% 53 Cyclically Adjusted FCF per Share is C$-0.11 as of Jun. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$2.06 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medexus Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was C$-0.032. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is C$-0.11 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 52.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Medexus Pharmaceuticals was 52.90% per year. The lowest was 41.20% per year. And the median was 47.05% per year.

As of today (2026-08-31), Medexus Pharmaceuticals's current stock price is C$5.06. Medexus Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was C$-0.11. Medexus Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Medexus Pharmaceuticals was 157.00. The lowest was 140.50. And the median was 144.00.


Medexus Pharmaceuticals  (TSX:MDP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Medexus Pharmaceuticals was 157.00. The lowest was 140.50. And the median was 144.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medexus Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Medexus Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -0.67 -0.40 -0.14 -0.07

Medexus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.03 0.02 -0.07 -0.11

TSX:MDP vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


TSX:MDP
53GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medexus Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.032/133.5265*133.5265
=-0.032

Current CPI (Jun. 2026) = 133.5265.

Medexus Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.286 101.765 -0.375
201612 -0.204 101.449 -0.269
201703 -0.182 102.634 -0.237
201706 -0.461 103.029 -0.597
201709 -0.145 103.345 -0.187
201712 -0.059 103.345 -0.076
201803 -0.160 105.004 -0.203
201806 -0.059 105.557 -0.075
201809 -0.063 105.636 -0.080
201812 -0.147 105.399 -0.186
201903 0.066 106.979 0.082
201906 -0.064 107.690 -0.079
201909 0.017 107.611 0.021
201912 -0.075 107.769 -0.093
202003 -0.130 107.927 -0.161
202006 0.279 108.401 0.344
202009 -0.002 108.164 -0.002
202012 -0.250 108.559 -0.307
202103 -0.422 110.298 -0.511
202106 -0.801 111.720 -0.957
202109 0.229 112.905 0.271
202112 -0.128 113.774 -0.150
202203 0.136 117.646 0.154
202206 -0.259 120.806 -0.286
202209 0.050 120.648 0.055
202212 -0.151 120.964 -0.167
202303 0.228 122.702 0.248
202306 0.275 124.203 0.296
202309 0.486 125.230 0.518
202312 0.307 125.072 0.328
202403 0.077 126.258 0.081
202406 0.457 127.522 0.479
202409 0.364 127.285 0.382
202412 0.367 127.364 0.385
202503 0.108 129.181 0.112
202506 0.156 129.892 0.160
202509 0.143 130.287 0.147
202512 0.323 130.366 0.331
202603 -0.477 132.262 -0.482
202606 -0.032 133.527 -0.032

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of C$-0.11 mean?
Medexus Pharmaceuticals (TSX:MDP) has a Cyclically Adjusted FCF per Share of C$-0.11 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Medexus Pharmaceuticals' current Cyclically Adjusted FCF per Share is C$-0.11. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ZTS?
Medexus Pharmaceuticals' Cyclically Adjusted FCF per Share of C$-0.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Cyclically Adjusted FCF per Share is C$-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$2.06, compared to a current price of C$5.06 — trading 145.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is C$-0.11. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Cyclically Adjusted FCF per Share is C$-0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.06 is trading 145.6% above its estimated GF Value™ of C$2.06. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Cyclically Adjusted FCF per Share: C$-0.11
  • GF Value™: C$2.06 vs. price of C$5.06 (145.6% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score

Get the complete analysis for TSX:MDP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.06
Price
C$2.06
GF Value